51
|
Profiling of differentially expressed microRNAs in arrhythmogenic right ventricular cardiomyopathy. Sci Rep 2016; 6:28101. [PMID: 27307080 PMCID: PMC4910108 DOI: 10.1038/srep28101] [Citation(s) in RCA: 43] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2016] [Accepted: 05/27/2016] [Indexed: 02/04/2023] Open
Abstract
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a kind of primary cardiomyopathy characterized by the fibro-fatty replacement of right ventricular myocardium. Currently, myocardial microRNAs have been reported to play critical role in the pathophysiology of cardiovascular pathophysiology. So far, the profiling of microRNAs in ARVC has not been described. In this study, we applied S-Poly (T) Plus method to investigate the expression profile of microRNAs in 24 ARVC patients heart samples. The tissue levels of 1078 human microRNAs were assessed and were compared with levels in a group of 24 healthy controls. Analysis of the area under the receiver operating characteristic curve (ROC) supported the 21 validated microRNAs to be miRNA signatures of ARVC, eleven microRNAs were significantly increased in ARVC heart tissues and ten microRNAs were significantly decreased. After functional enrichment analysis, miR-21-5p and miR-135b were correlated with Wnt and Hippo pathway, which might involve in the molecular pathophysiology of ARVC. Overall, our data suggested that myocardial microRNAs were involved in the pathophysiology of ARVC, miR-21-5p and miR-135b were significantly associated with both the myocardium adipose and fibrosis, which was a potential disease pathway for ARVC and might to be useful as therapeutic targets for ARVC.
Collapse
|
52
|
Marques FZ, Vizi D, Khammy O, Mariani JA, Kaye DM. The transcardiac gradient of cardio-microRNAs in the failing heart. Eur J Heart Fail 2016; 18:1000-8. [DOI: 10.1002/ejhf.517] [Citation(s) in RCA: 122] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/04/2015] [Revised: 02/08/2016] [Accepted: 03/01/2016] [Indexed: 11/07/2022] Open
Affiliation(s)
- Francine Z. Marques
- Heart Failure Research Group; Baker IDI Heart and Diabetes Research Institute VIC; Australia
| | - Donna Vizi
- Heart Centre; Alfred Hospital; Melbourne VIC Australia
| | - Ouda Khammy
- Heart Failure Research Group; Baker IDI Heart and Diabetes Research Institute VIC; Australia
| | - Justin A. Mariani
- Heart Failure Research Group; Baker IDI Heart and Diabetes Research Institute VIC; Australia
- Heart Centre; Alfred Hospital; Melbourne VIC Australia
| | - David M. Kaye
- Heart Failure Research Group; Baker IDI Heart and Diabetes Research Institute VIC; Australia
- Heart Centre; Alfred Hospital; Melbourne VIC Australia
| |
Collapse
|
53
|
Wong LL, Wang J, Liew OW, Richards AM, Chen YT. MicroRNA and Heart Failure. Int J Mol Sci 2016; 17:502. [PMID: 27058529 PMCID: PMC4848958 DOI: 10.3390/ijms17040502] [Citation(s) in RCA: 92] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2016] [Revised: 03/18/2016] [Accepted: 03/23/2016] [Indexed: 12/12/2022] Open
Abstract
Heart failure (HF) imposes significant economic and public health burdens upon modern society. It is known that disturbances in neurohormonal status play an important role in the pathogenesis of HF. Therapeutics that antagonize selected neurohormonal pathways, specifically the renin-angiotensin-aldosterone and sympathetic nervous systems, have significantly improved patient outcomes in HF. Nevertheless, mortality remains high with about 50% of HF patients dying within five years of diagnosis thus mandating ongoing efforts to improve HF management. The discovery of short noncoding microRNAs (miRNAs) and our increasing understanding of their functions, has presented potential therapeutic applications in complex diseases, including HF. Results from several genome-wide miRNA studies have identified miRNAs differentially expressed in HF cohorts suggesting their possible involvement in the pathogenesis of HF and their potential as both biomarkers and as therapeutic targets. Unravelling the functional relevance of miRNAs within pathogenic pathways is a major challenge in cardiovascular research. In this article, we provide an overview of the role of miRNAs in the cardiovascular system. We highlight several HF-related miRNAs reported from selected cohorts and review their putative roles in neurohormonal signaling.
Collapse
Affiliation(s)
- Lee Lee Wong
- Cardiovascular Research Institute, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, #08-01, MD6 Centre for Translational Medicine, 14 Medical Drive, Singapore 117599, Singapore.
| | - Juan Wang
- Cardiovascular Research Institute, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, #08-01, MD6 Centre for Translational Medicine, 14 Medical Drive, Singapore 117599, Singapore.
| | - Oi Wah Liew
- Cardiovascular Research Institute, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, #08-01, MD6 Centre for Translational Medicine, 14 Medical Drive, Singapore 117599, Singapore.
| | - Arthur Mark Richards
- Cardiovascular Research Institute, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, #08-01, MD6 Centre for Translational Medicine, 14 Medical Drive, Singapore 117599, Singapore.
- Cardiac Department, National University Health System, Tower Block Level 9, 1E Kent Ridge Road, Singapore 119228, Singapore.
- Christchurch Heart Institute, Department of Medicine, University of Otago, PO Box 4345, Christchurch 8014, New Zealand.
| | - Yei-Tsung Chen
- Cardiovascular Research Institute, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, #08-01, MD6 Centre for Translational Medicine, 14 Medical Drive, Singapore 117599, Singapore.
| |
Collapse
|
54
|
Napoli C, Grimaldi V, De Pascale MR, Sommese L, Infante T, Soricelli A. Novel epigenetic-based therapies useful in cardiovascular medicine. World J Cardiol 2016; 8:211-219. [PMID: 26981216 PMCID: PMC4766271 DOI: 10.4330/wjc.v8.i2.211] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/30/2015] [Revised: 09/28/2015] [Accepted: 12/18/2015] [Indexed: 02/06/2023] Open
Abstract
Epigenetic modifications include DNA methylation, histone modifications, and microRNA. Gene alterations have been found to be associated with cardiovascular diseases, and epigenetic mechanisms are continuously being studied to find new useful strategies for the clinical management of afflicted patients. Numerous cardiovascular disorders are characterized by the abnormal methylation of CpG islands and so specific drugs that could inhibit DNA methyltransferase directly or by reducing its gene expression (e.g., hydralazine and procainamide) are currently under investigation. The anti-proliferative and anti-inflammatory properties of histone deacetylase inhibitors and their cardio-protective effects have been confirmed in preclinical studies. Furthermore, the regulation of the expression of microRNA targets through pharmacological tools is still under development. Indeed, large controlled trials are required to establish whether current possible candidate antisense microRNAs could offer better therapeutic benefits in clinical practice. Here, we updated therapeutic properties, side effects, and feasibility of emerging epigenetic-based strategies in cardiovascular diseases by highlighting specific problematic issues that still affect the development of large scale novel therapeutic protocols.
Collapse
|
55
|
Vegter EL, van der Meer P, de Windt LJ, Pinto YM, Voors AA. MicroRNAs in heart failure: from biomarker to target for therapy. Eur J Heart Fail 2016; 18:457-68. [DOI: 10.1002/ejhf.495] [Citation(s) in RCA: 190] [Impact Index Per Article: 23.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/28/2015] [Revised: 12/08/2015] [Accepted: 12/14/2015] [Indexed: 11/08/2022] Open
Affiliation(s)
- Eline L. Vegter
- Department of Cardiology; University Medical Centre Groningen; Hanzeplein 1, 9713 GZ Groningen the Netherlands
| | - Peter van der Meer
- Department of Cardiology; University Medical Centre Groningen; Hanzeplein 1, 9713 GZ Groningen the Netherlands
| | - Leon J. de Windt
- Department of Cardiology; CARIM School for Cardiovascular Diseases, Maastricht University; Maastricht the Netherlands
| | - Yigal M. Pinto
- Department of Cardiology; Heart Failure Research Centre, Academic Medical Centre; Amsterdam the Netherlands
| | - Adriaan A. Voors
- Department of Cardiology; University Medical Centre Groningen; Hanzeplein 1, 9713 GZ Groningen the Netherlands
| |
Collapse
|
56
|
Weckbach LT, Grabmaier U, Clauss S, Wakili R. MicroRNAs as a diagnostic tool for heart failure and atrial fibrillation. Curr Opin Pharmacol 2016; 27:24-30. [PMID: 26852213 DOI: 10.1016/j.coph.2016.01.001] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2015] [Accepted: 01/12/2016] [Indexed: 01/24/2023]
Abstract
MicroRNAs (miRNAs) are small non-coding RNAs, which are directly involved in the regulation of post-transcriptional gene expression. Their biological function represents a repression of protein expression of the targeted messenger-RNA(s). Expression of several miRNAs is somehow tissue-specific or cell-specific and their expression pattern can reflect an underlying pathophysiological condition. Beyond this biological function their role as potential biomarkers has been emerged in the past years. This was based on the fact that miRNAs can be detected in blood samples (serum or plasma) in a surprisingly stable form, by contrast to mRNAs. This fact made miRNAs interesting candidates for biomarkers providing information with respect to a potentially ongoing pathophysiological condition and could thereby have an impact on specific treatment strategies in patients. In this review we try to provide an overview of the potential role of miRNAs as a diagnostic tool in atrial fibrillation and heart failure patients taken different methodological aspects and distinct type of patients into account.
Collapse
Affiliation(s)
- Ludwig T Weckbach
- Department of Medicine I, University Hospital Munich, Campus Grosshadern, Ludwig-Maximilians-University Munich, Germany
| | - Ulrich Grabmaier
- Department of Medicine I, University Hospital Munich, Campus Grosshadern, Ludwig-Maximilians-University Munich, Germany
| | - Sebastian Clauss
- Department of Medicine I, University Hospital Munich, Campus Grosshadern, Ludwig-Maximilians-University Munich, Germany; Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA; DZHK (German Centre for Cardiovascular Research), Partner Site Munich, Germany
| | - Reza Wakili
- Department of Medicine I, University Hospital Munich, Campus Grosshadern, Ludwig-Maximilians-University Munich, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Munich, Germany.
| |
Collapse
|
57
|
Bekris LM, Leverenz JB. The biomarker and therapeutic potential of miRNA in Alzheimer's disease. Neurodegener Dis Manag 2016; 5:61-74. [PMID: 25711455 DOI: 10.2217/nmt.14.52] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Alzheimer's disease (AD) is the most common cause of dementia. Currently, a clinical diagnosis of AD is based on evidence of both cognitive and functional decline. Progression is monitored by detailed clinical evaluations over many months to years. It is increasingly clear that to advance disease-modifying therapies for AD, patients must be identified and treated early, before obvious cognitive and functional changes. In addition, better methods are needed to sensitively monitor progression of disease and therapeutic efficacy. Therefore, considerable research has focused on characterizing biomarkers that can identify the disease early as well as accurately monitor disease progression. miRNA offer a unique opportunity for biomarker development. Here, we review research focused on characterizing miRNA as potential biomarkers and as a treatment for disease.
Collapse
Affiliation(s)
- Lynn M Bekris
- Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
| | | |
Collapse
|
58
|
Schmitter D, Voors AA, van der Harst P. HFpEF vs. HFrEF: can microRNAs advance the diagnosis? Eur J Heart Fail 2016; 17:351-4. [PMID: 25828905 DOI: 10.1002/ejhf.259] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/02/2015] [Accepted: 02/03/2015] [Indexed: 01/15/2023] Open
|
59
|
Schulte C, Westermann D, Blankenberg S, Zeller T. Diagnostic and prognostic value of circulating microRNAs in heart failure with preserved and reduced ejection fraction. World J Cardiol 2015; 7:843-860. [PMID: 26730290 PMCID: PMC4691811 DOI: 10.4330/wjc.v7.i12.843] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/28/2015] [Revised: 08/28/2015] [Accepted: 10/13/2015] [Indexed: 02/07/2023] Open
Abstract
microRNAs (miRNAs) are powerful regulators of posttranscriptional gene expression and play an important role in pathophysiological processes. Circulating miRNAs can be quantified in body liquids and are promising biomarkers in numerous diseases. In cardiovascular disease miRNAs have been proven to be reliable diagnostic biomarkers for different disease entities. In cardiac fibrosis (CF) and heart failure (HF) dysregulated circulating miRNAs have been identified, indicating their promising applicability as diagnostic biomarkers. Some miRNAs were successfully tested in risk stratification of HF implementing their potential use as prognostic biomarkers. In this respect miRNAs might soon be implemented in diagnostic clinical routine. In the young field of miRNA based research advances have been made in identifying miRNAs as potential targets for the treatment of experimental CF and HF. Promising study results suggest their potential future application as therapeutic agents in treatment of cardiovascular disease. This article summarizes the current state of the various aspects of miRNA research in the field of CF and HF with reduced ejection fraction as well as preserved ejection fraction. The review provides an overview of the application of circulating miRNAs as biomarkers in CF and HF and current approaches to therapeutically utilize miRNAs in this field of cardiovascular disease.
Collapse
|
60
|
Keller A, Meese E. Can circulating miRNAs live up to the promise of being minimal invasive biomarkers in clinical settings? WILEY INTERDISCIPLINARY REVIEWS-RNA 2015; 7:148-56. [PMID: 26670867 DOI: 10.1002/wrna.1320] [Citation(s) in RCA: 56] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/13/2015] [Revised: 10/26/2015] [Accepted: 10/28/2015] [Indexed: 12/23/2022]
Abstract
MicroRNAs have been discussed as non- or minimal invasive biomarkers with a remarkable extracellular stability. Despite a multitude of studies in basic research, there are only few independent validation studies on blood-born miRNAs as disease markers. Toward clinical applications numerous obstacles still need to be overcome. They are of technical origin but also fundamentally associated with the source and the nature of miRNAs. Here, we emphasize on potential confounding factors, the nature and the source of miRNAs. We recently showed that age and gender could influence the pattern of circulating miRNAs. On the cellular level, the miRNA pattern differs between plasma and serum preparations. On the molecular level, one has to differentiate between extracellular miRNAs that are encapsulated in microvesicles or bound to proteins or high-density lipoproteins. Using whole blood as source for miRNAs helps to minimize miRNA expression changes due to environmental influences and allows attributing miRNA changes to their cells of origin like B-cells and T-cells. Moreover, unambiguous annotation and differentiation from other noncoding RNAs can be challenging. Even not all miRNAs deposited in miRBase do necessarily represent true miRNAs, just a fraction of miRNAs in the reference database have been experimentally validated by Northern blotting. Functional evidence for a true miRNA should be obtained by cloning the precursor miRNA and by subsequent detection of the processed mature form in host cells. Surprisingly, attempts to finally confirm a true miRNA are frequently postponed until evidence has been established for a likely value as biomarker.
Collapse
Affiliation(s)
- Andreas Keller
- Chair for Clinical Bioinformatics, Saarland University, University Hospital, Saarbrücken, Germany
| | - Eckart Meese
- Institute of Human Genetics, Saarland University, University Hospital, Homburg, Germany
| |
Collapse
|
61
|
Hofmann S, Huang Y, Paulicka P, Kappel A, Katus HA, Keller A, Meder B, Stähler CF, Gumbrecht W. Double-Stranded Ligation Assay for the Rapid Multiplex Quantification of MicroRNAs. Anal Chem 2015; 87:12104-11. [DOI: 10.1021/acs.analchem.5b02850] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Stefan Hofmann
- Department
of Bioinformatics, University of Würzburg, Würzburg, 97074, Germany
| | - Yiwei Huang
- Technology Center,
Siemens Healthcare, Erlangen, 91058, Germany
| | - Peter Paulicka
- Technology Center,
Siemens Healthcare, Erlangen, 91058, Germany
| | - Andreas Kappel
- Technology Center,
Siemens Healthcare, Erlangen, 91058, Germany
| | - Hugo A. Katus
- Internal
Medicine III, University Hospital Heidelberg, Heidelberg, 69120, Germany
| | - Andreas Keller
- Clinical
Bioinformatics, Medical Faculty, Saarland University, Saarbrücken, 66123, Germany
| | - Benjamin Meder
- Internal
Medicine III, University Hospital Heidelberg, Heidelberg, 69120, Germany
| | | | | |
Collapse
|
62
|
Seronde MF, Vausort M, Gayat E, Goretti E, Ng LL, Squire IB, Vodovar N, Sadoune M, Samuel JL, Thum T, Solal AC, Laribi S, Plaisance P, Wagner DR, Mebazaa A, Devaux Y. Circulating microRNAs and Outcome in Patients with Acute Heart Failure. PLoS One 2015; 10:e0142237. [PMID: 26580972 PMCID: PMC4651494 DOI: 10.1371/journal.pone.0142237] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2015] [Accepted: 10/18/2015] [Indexed: 02/06/2023] Open
Abstract
Background The biomarker value of circulating microRNAs (miRNAs) has been extensively addressed in patients with acute coronary syndrome. However, prognostic performances of miRNAs in patients with acute heart failure (AHF) has received less attention. Methods A test cohort of 294 patients with acute dyspnea (236 AHF and 58 non-AHF) and 44 patients with stable chronic heart failure (CHF), and an independent validation cohort of 711 AHF patients, were used. Admission levels of miR-1/-21/-23/-126/-423-5p were assessed in plasma samples. Results In the test cohort, admission levels of miR-1 were lower in AHF and stable CHF patients compared to non-AHF patients (p = 0.0016). Levels of miR-126 and miR-423-5p were lower in AHF and in non-AHF patients compared to stable CHF patients (both p<0.001). Interestingly, admission levels of miR-423-5p were lower in patients who were re-admitted to the hospital in the year following the index hospitalization compared to patients who were not (p = 0.0001). Adjusted odds ratio [95% confidence interval] for one-year readmission was 0.70 [0.53–0.93] for miR-423-5p (p = 0.01). In the validation cohort, admission levels of miR-423-5p predicted 1-year mortality with an adjusted odds ratio [95% confidence interval] of 0.54 [0.36–0.82], p = 0.004. Patients within the lowest quartile of miR-423-5p were at high risk of long-term mortality (p = 0.02). Conclusions In AHF patients, low circulating levels of miR-423-5p at presentation are associated with a poor long-term outcome. This study supports the value of miR-423-5p as a prognostic biomarker of AHF.
Collapse
Affiliation(s)
- Marie-France Seronde
- Department of Cardiology, EA3920, University Hospital, Besançon, France
- UMRS 942 Inserm, University Paris Diderot, Paris, France
| | - Mélanie Vausort
- Laboratory of Cardiovascular Research, Centre de Recherche Public de la Santé, Luxembourg, Luxembourg
| | - Etienne Gayat
- UMRS 942 Inserm, University Paris Diderot, Paris, France
- Department of Anesthesiology and Critical Care Saint Louis—Lariboisière Hospital, Paris, France
| | - Emeline Goretti
- Laboratory of Cardiovascular Research, Centre de Recherche Public de la Santé, Luxembourg, Luxembourg
| | - Leong L. Ng
- University of Leicester and National Institute for Health Research, Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, United Kingdom
| | - Iain B. Squire
- University of Leicester and National Institute for Health Research, Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, United Kingdom
| | | | - Malha Sadoune
- UMRS 942 Inserm, University Paris Diderot, Paris, France
| | | | - Thomas Thum
- Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover, Germany
| | - Alain Cohen Solal
- UMRS 942 Inserm, University Paris Diderot, Paris, France
- Department of Cardiology, Lariboisière Hospital, Paris, France
| | - Said Laribi
- UMRS 942 Inserm, University Paris Diderot, Paris, France
- Department of Emergency Medicine, Lariboisière Hospital, Paris, France
| | - Patrick Plaisance
- UMRS 942 Inserm, University Paris Diderot, Paris, France
- Department of Emergency Medicine, Lariboisière Hospital, Paris, France
| | - Daniel R. Wagner
- Laboratory of Cardiovascular Research, Centre de Recherche Public de la Santé, Luxembourg, Luxembourg
| | | | - Yvan Devaux
- Laboratory of Cardiovascular Research, Centre de Recherche Public de la Santé, Luxembourg, Luxembourg
- * E-mail:
| | | |
Collapse
|
63
|
Ovchinnikova ES, Schmitter D, Vegter EL, ter Maaten JM, Valente MA, Liu LC, van der Harst P, Pinto YM, de Boer RA, Meyer S, Teerlink JR, O'Connor CM, Metra M, Davison BA, Bloomfield DM, Cotter G, Cleland JG, Mebazaa A, Laribi S, Givertz MM, Ponikowski P, van der Meer P, van Veldhuisen DJ, Voors AA, Berezikov E. Signature of circulating microRNAs in patients with acute heart failure. Eur J Heart Fail 2015; 18:414-23. [DOI: 10.1002/ejhf.332] [Citation(s) in RCA: 140] [Impact Index Per Article: 15.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/29/2015] [Revised: 06/11/2015] [Accepted: 06/11/2015] [Indexed: 12/12/2022] Open
Affiliation(s)
- Ekaterina S. Ovchinnikova
- Department of Cardiology; University Medical Center Groningen; Groningen The Netherlands
- European Research Institute for the Biology of Ageing and University Medical Center Groningen, University of Groningen; Groningen The Netherlands
| | | | - Eline L. Vegter
- Department of Cardiology; University Medical Center Groningen; Groningen The Netherlands
| | - Jozine M. ter Maaten
- Department of Cardiology; University Medical Center Groningen; Groningen The Netherlands
| | - Mattia A.E. Valente
- Department of Cardiology; University Medical Center Groningen; Groningen The Netherlands
| | - Licette C.Y. Liu
- Department of Cardiology; University Medical Center Groningen; Groningen The Netherlands
| | - Pim van der Harst
- Department of Cardiology; University Medical Center Groningen; Groningen The Netherlands
| | | | - Rudolf A. de Boer
- Department of Cardiology; University Medical Center Groningen; Groningen The Netherlands
| | - Sven Meyer
- Department of Cardiology; University Medical Center Groningen; Groningen The Netherlands
| | - John R. Teerlink
- University of California at San Francisco and San Francisco Veterans Affairs Medical Center; San Francisco CA USA
| | | | - Marco Metra
- Cardiology, The Department of Medical and Surgical Specialties; Radiological Sciences, and Public Health; University of Brescia; Brescia Italy
| | | | | | | | - John G. Cleland
- National Heart & Lung Institute, Royal Brompton & Harefield Hospitals; Imperial College; London UK
| | - Alexandre Mebazaa
- University Paris Diderot, U942 INSERM, AP-HP, St Louis-Lariboisière University Hospitals; Department of Anesthesiology and Critical Care and Burn Unit; Paris France
| | - Said Laribi
- U942 INSERM, AP-HP, St Louis-Lariboisière University Hospitals; Department of Emergency Medicine; Paris France
| | | | | | - Peter van der Meer
- Department of Cardiology; University Medical Center Groningen; Groningen The Netherlands
| | - Dirk J. van Veldhuisen
- Department of Cardiology; University Medical Center Groningen; Groningen The Netherlands
| | - Adriaan A. Voors
- Department of Cardiology; University Medical Center Groningen; Groningen The Netherlands
| | - Eugene Berezikov
- European Research Institute for the Biology of Ageing and University Medical Center Groningen, University of Groningen; Groningen The Netherlands
| |
Collapse
|
64
|
Wei XJ, Han M, Yang FY, Wei GC, Liang ZG, Yao H, Ji CW, Xie RS, Gong CL, Tian Y. Biological significance of miR-126 expression in atrial fibrillation and heart failure. ACTA ACUST UNITED AC 2015; 48:983-9. [PMID: 26313139 PMCID: PMC4671524 DOI: 10.1590/1414-431x20154590] [Citation(s) in RCA: 48] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2014] [Accepted: 04/27/2015] [Indexed: 12/22/2022]
Abstract
We investigated the biological significance of microRNA-126 (miR-126) expression in patients with atrial fibrillation (AF) and/or heart failure (HF) to examine the possible mechanism of miR-126-dependent AF and development of HF. A total of 103 patients were divided into three groups: AF group (18 men and 17 women, mean age: 65.62±12.72 years), HF group (17 men and 15 women, mean age: 63.95±19.71 years), and HF-AF group (20 men and 16 women, mean age: 66.56±14.37 years). Quantitative real-time PCR was used to measure relative miR-126 expression as calculated by the 2-ΔΔCt method. miR-126 was frequently downregulated in the 3 patient groups compared with controls. This reduction was significantly lower in permanent and persistent AF patients than in those with paroxysmal AF (P<0.05, t-test). Moreover, miR-126 expression was markedly lower in the HF-AF group compared with the AF and HF groups. The 3 patient groups had higher N-terminal prohormone brain natriuretic peptide (NT-proBNP) levels, lower left ventricular ejection fraction (LVEF), larger left atrial diameter, and higher cardiothoracic ratio compared with controls. There were significant differences in NT-proBNP levels and LVEF among the AF, HF, and HF-AF groups. Pearson correlation analysis showed that relative miR-126 expression was positively associated with LVEF, logarithm of NT-proBNP, left atrial diameter, cardiothoracic ratio, and age in HF-AF patients. Multiple linear regression analysis showed that miR-126 expression was positively correlated with LVEF, but negatively correlated with the logarithm of NT-pro BNP and the cardiothoracic ratio (all P<0.05). Serum miR-126 levels could serve as a potential candidate biomarker for evaluating the severity of AF and HF. However, to confirm these results, future studies with a larger and diverse patient population are necessary.
Collapse
Affiliation(s)
- X J Wei
- Intensive Care Unit, The People's Hospital of Laiwu City, Laiwu City, Shandong Province, China
| | - M Han
- Emergency Department, The People's Hospital of Laiwu City, Laiwu City, Shandong Province, China
| | - F Y Yang
- Intensive Care Unit, The People's Hospital of Laiwu City, Laiwu City, Shandong Province, China
| | - G C Wei
- Intensive Care Unit, The People's Hospital of Laiwu City, Laiwu City, Shandong Province, China
| | - Z G Liang
- Intensive Care Unit, The People's Hospital of Laiwu City, Laiwu City, Shandong Province, China
| | - H Yao
- Intensive Care Unit, The People's Hospital of Laiwu City, Laiwu City, Shandong Province, China
| | - C W Ji
- Intensive Care Unit, The People's Hospital of Laiwu City, Laiwu City, Shandong Province, China
| | - R S Xie
- Intensive Care Unit, The People's Hospital of Laiwu City, Laiwu City, Shandong Province, China
| | - C L Gong
- Intensive Care Unit, The People's Hospital of Laiwu City, Laiwu City, Shandong Province, China
| | - Y Tian
- Intensive Care Unit, The People's Hospital of Laiwu City, Laiwu City, Shandong Province, China
| |
Collapse
|
65
|
Kayvanpour E, Mansi T, Sedaghat-Hamedani F, Amr A, Neumann D, Georgescu B, Seegerer P, Kamen A, Haas J, Frese KS, Irawati M, Wirsz E, King V, Buss S, Mereles D, Zitron E, Keller A, Katus HA, Comaniciu D, Meder B. Towards Personalized Cardiology: Multi-Scale Modeling of the Failing Heart. PLoS One 2015; 10:e0134869. [PMID: 26230546 PMCID: PMC4521877 DOI: 10.1371/journal.pone.0134869] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2015] [Accepted: 07/14/2015] [Indexed: 01/14/2023] Open
Abstract
BACKGROUND Despite modern pharmacotherapy and advanced implantable cardiac devices, overall prognosis and quality of life of HF patients remain poor. This is in part due to insufficient patient stratification and lack of individualized therapy planning, resulting in less effective treatments and a significant number of non-responders. METHODS AND RESULTS State-of-the-art clinical phenotyping was acquired, including magnetic resonance imaging (MRI) and biomarker assessment. An individualized, multi-scale model of heart function covering cardiac anatomy, electrophysiology, biomechanics and hemodynamics was estimated using a robust framework. The model was computed on n=46 HF patients, showing for the first time that advanced multi-scale models can be fitted consistently on large cohorts. Novel multi-scale parameters derived from the model of all cases were analyzed and compared against clinical parameters, cardiac imaging, lab tests and survival scores to evaluate the explicative power of the model and its potential for better patient stratification. Model validation was pursued by comparing clinical parameters that were not used in the fitting process against model parameters. CONCLUSION This paper illustrates how advanced multi-scale models can complement cardiovascular imaging and how they could be applied in patient care. Based on obtained results, it becomes conceivable that, after thorough validation, such heart failure models could be applied for patient management and therapy planning in the future, as we illustrate in one patient of our cohort who received CRT-D implantation.
Collapse
Affiliation(s)
- Elham Kayvanpour
- Department of Medicine III, University of Heidelberg, Heidelberg, Germany
- DZHK (German Centre for Cardiovascular Research), Heidelberg, Germany
| | - Tommaso Mansi
- Siemens Corporation, Corporate Technology, Imaging and Computer Vision, Princeton, New Jersey, United States of America
| | - Farbod Sedaghat-Hamedani
- Department of Medicine III, University of Heidelberg, Heidelberg, Germany
- DZHK (German Centre for Cardiovascular Research), Heidelberg, Germany
| | - Ali Amr
- Department of Medicine III, University of Heidelberg, Heidelberg, Germany
- DZHK (German Centre for Cardiovascular Research), Heidelberg, Germany
| | - Dominik Neumann
- Siemens Corporation, Corporate Technology, Imaging and Computer Vision, Princeton, New Jersey, United States of America
| | - Bogdan Georgescu
- Siemens Corporation, Corporate Technology, Imaging and Computer Vision, Princeton, New Jersey, United States of America
| | - Philipp Seegerer
- Siemens Corporation, Corporate Technology, Imaging and Computer Vision, Princeton, New Jersey, United States of America
| | - Ali Kamen
- Siemens Corporation, Corporate Technology, Imaging and Computer Vision, Princeton, New Jersey, United States of America
| | - Jan Haas
- Department of Medicine III, University of Heidelberg, Heidelberg, Germany
- DZHK (German Centre for Cardiovascular Research), Heidelberg, Germany
| | - Karen S. Frese
- Department of Medicine III, University of Heidelberg, Heidelberg, Germany
- DZHK (German Centre for Cardiovascular Research), Heidelberg, Germany
| | - Maria Irawati
- Department of Medicine III, University of Heidelberg, Heidelberg, Germany
| | - Emil Wirsz
- Siemens AG, Corporate Technology, Erlangen, Germany
| | - Vanessa King
- Siemens Corporation, Corporate Technology, Sensor Technologies, Princeton, New Jersey, United States of America
| | - Sebastian Buss
- Department of Medicine III, University of Heidelberg, Heidelberg, Germany
| | - Derliz Mereles
- Department of Medicine III, University of Heidelberg, Heidelberg, Germany
| | - Edgar Zitron
- Department of Medicine III, University of Heidelberg, Heidelberg, Germany
| | - Andreas Keller
- Biomarker Discovery Center Heidelberg, Heidelberg, Germany
- Department of Human Genetics, Saarland University, Homburg, Germany
| | - Hugo A. Katus
- Department of Medicine III, University of Heidelberg, Heidelberg, Germany
- DZHK (German Centre for Cardiovascular Research), Heidelberg, Germany
- Klaus Tschira Institute for Computational Cardiology, Heidelberg, Germany
| | - Dorin Comaniciu
- Siemens Corporation, Corporate Technology, Imaging and Computer Vision, Princeton, New Jersey, United States of America
| | - Benjamin Meder
- Department of Medicine III, University of Heidelberg, Heidelberg, Germany
- DZHK (German Centre for Cardiovascular Research), Heidelberg, Germany
- Klaus Tschira Institute for Computational Cardiology, Heidelberg, Germany
| |
Collapse
|
66
|
Abstract
Heart failure is a common and disabling disease with high mortality that carries substantial societal costs. Current therapeutic strategies are aimed at relieving symptoms, avoiding hospitalization, and prolonging life, but disease progression is ultimately inevitable. MicroRNAs (miRNAs) are short, non-coding RNA molecules with pervasive roles in eukaryotic biology, annealing to complimentary sites on target mRNAs, and repressing gene expression. The fact that miRNAs are dysregulated in many human disorders, including cardiovascular disease, and the relative ease with which endogenous miRNA expression can be altered using synthetic antisense oligos has stirred enthusiasm for these molecules as potential drug targets. The aim of this review article was to summarize the current knowledge on the roles of miRNA in the pathophysiology of heart failure as well as the use of miRNAs as therapeutic targets and diagnostic tools for the disease.
Collapse
Affiliation(s)
- Olof Gidlöf
- Department of Cardiology, Clinical Sciences, Lund University , Lund , Sweden
| | | |
Collapse
|
67
|
Lai KB, Sanderson JE, Izzat MB, Yu CM. Micro-RNA and mRNA myocardial tissue expression in biopsy specimen from patients with heart failure. Int J Cardiol 2015; 199:79-83. [PMID: 26188824 DOI: 10.1016/j.ijcard.2015.07.043] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/21/2015] [Revised: 07/07/2015] [Accepted: 07/07/2015] [Indexed: 12/27/2022]
Abstract
AIMS There is increasing evidence that changes in microRNA (miRNA) expression occur in chronic heart failure and these may be involved in the pathogenesis. In this study we have explored the expression of selected myocyte and fibroblast-related microRNAs and messenger RNAs (mRNAs) that are associated with hypertrophy, apoptosis and fibrosis in biopsy specimens from patients with relatively new onset heart failure compared to a group of patients without heart failure. METHODS AND RESULTS Myocardial biopsy specimens taken from Chinese patients presenting with recent heart failure were compared with a group of patients without heart failure undergoing routine cardiac surgery (n=34). miRNAs (miR-1, -21, -23, -29, -30, -130, -133, -195, -199, -208, and -320) and corresponding mRNA expression were measured by real-time quantitative-PCR method. miR-1, -21, -23, -29, -130, -195 and -199 were significantly up-regulated in the heart failure group when compared to those without heart failure (all p<0.01). However, miR-30, -133, -208 and -320 were not significantly different. Related mRNAs (casp3, coll I, coll III and TGF) were also significantly up-regulated (all p<0.05) in the heart failure group. CONCLUSION Certain selected microRNAs involved in apoptosis, hypertrophy and fibrosis are up-regulated in the myocardium of patients with a clinical history of heart failure compared to those without. These specific miRNAs may be the most suitable for circulating biomarkers in the early stages of chronic heart failure and possibly future therapeutic targets.
Collapse
Affiliation(s)
- Ka-Bik Lai
- Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR
| | - John E Sanderson
- Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR
| | - Mohammad Bashar Izzat
- Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR
| | - Cheuk-Man Yu
- Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR.
| |
Collapse
|
68
|
van den Hoogen P, van den Akker F, Deddens JC, Sluijter JPG. Heart Failure in Chronic Myocarditis: A Role for microRNAs? Curr Genomics 2015; 16:88-94. [PMID: 26085807 PMCID: PMC4467309 DOI: 10.2174/1389202916999150120153344] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2014] [Revised: 12/20/2014] [Accepted: 01/06/2015] [Indexed: 12/22/2022] Open
Abstract
Myocarditis is an inflammatory disease of the heart, which can persist over a long time. During this time, known as the chronic phase of myocarditis, ongoing inflammation damages the cardiomyocytes. The loss of cardiac cells culminates in the development of dilated cardiomyopathy, often followed by non-ischemic heart failure due to diminished cardiac function. During the course of the disease, expression levels of non-coding small RNAs, called microRNAs (miRNAs), change. Although mainly studied in the acute setting, some of these changes in expression level appear to persist in the chronic phase. In addition to being a much-needed diagnostic tool, these miRNA could provide new treatment options. miRNA-based intervention strategies already showed promising results in the treatment of ischemic cardiovascular diseases in preclinical animal models. By implementing more knowledge on the role of miRNAs in the progression towards heart failure, this can potentially be used in the development of miRNA-based therapeutic interventions in the treatment of myocarditis and thereby preventing the progression towards heart failure. The first part of this review will focus on the natural course of myocarditis and the progression towards heart failure. Secondly, we will discuss the current knowledge on alterations of miRNA expression patterns, and suggest some possible future interventions.
Collapse
Affiliation(s)
- P van den Hoogen
- Department of Cardiology, University Medical Center Utrecht, the Netherlands; ; ICIN - Netherlands Heart Institute, Utrecht, The Netherlands
| | - F van den Akker
- Department of Cardiology, University Medical Center Utrecht, the Netherlands
| | - J C Deddens
- Department of Cardiology, University Medical Center Utrecht, the Netherlands
| | - J P G Sluijter
- Department of Cardiology, University Medical Center Utrecht, the Netherlands; ; ICIN - Netherlands Heart Institute, Utrecht, The Netherlands
| |
Collapse
|
69
|
Kuehl U, Lassner D, Gast M, Stroux A, Rohde M, Siegismund C, Wang X, Escher F, Gross M, Skurk C, Tschoepe C, Loebel M, Scheibenbogen C, Schultheiss HP, Poller W. Differential Cardiac MicroRNA Expression Predicts the Clinical Course in Human Enterovirus Cardiomyopathy. Circ Heart Fail 2015; 8:605-18. [PMID: 25761932 DOI: 10.1161/circheartfailure.114.001475] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/20/2014] [Accepted: 03/09/2015] [Indexed: 01/03/2023]
Abstract
BACKGROUND Investigation of disease pathogenesis confined to protein-coding regions of the genome may be incomplete because many noncoding variants are associated with disease. We aimed to identify novel predictive markers for the course of enterovirus (CVB3) cardiomyopathy by screening for noncoding elements influencing the grossly different antiviral capacity of individual patients. METHODS AND RESULTS Transcriptome mapping of CVB3 cardiomyopathy patients revealed distinctive cardiac microRNA (miR) patterns associated with spontaneous virus clearance and recovery (CVB3-ELIM) versus virus persistence and progressive clinical deterioration (CVB3-PERS). Profiling of protein-coding genes and 754 miRs in endomyocardial biopsies of test cohorts was performed at their initial presentation, and those spontaneously eliminating the virus were compared with those with virus persistence on follow-up. miR profiling revealed highly significant differences in cardiac levels of 16 miRs, but not of protein-coding genes. Evaluation of this primary distinctive miR pattern in validation cohorts, and multivariate receiver operating characteristic curve analysis, confirmed this pattern as highly predictive for disease course (area under the curve, 0.897±0.071; 95% confidence interval, 0.758-1.000). Eight miRs were strongly induced in CVB3-PERS (miRs 135b, 155, 190, 422a, 489, 590, 601, 1290), but undetectable in CVB3-ELIM or controls. They are predicted to target multiple immune response genes, and 2 of these were confirmed by antisense-mediated ablation of miRs 135b, 190, and 422a in the monocytic THP-1 cell line. CONCLUSIONS An immediate clinical application of the data is cardiac miR profiling to assess the risk of virus persistence and progressive clinical deterioration in CVB3 cardiomyopathy. Patients at risk are eligible for immediate antiviral therapy to minimize irreversible cardiac damage.
Collapse
Affiliation(s)
- Uwe Kuehl
- From the Department of Cardiology and Pneumology (U.K., M.G., X.W., F.E., M.G., C. Skurk, C.T., H.-P.S., W.P.), Institute for Biometry and Clinical Epidemiology, Campus Benjamin Franklin (A.S.), Institute for Medical Immunology, Campus Virchow Klinikum (M.L., C. Scheibenbogen), Berlin Center for Regenerative Therapies (BCRT) (C.T., M.L., C. Scheibenbogen, W.P.), Charité-Universitätsmedizin Berlin, Berlin, Germany; and Institute for Cardiac Diagnostics and Therapy (IKDT), Berlin, Germany (D.L., M.R., C. Siegismund)
| | - Dirk Lassner
- From the Department of Cardiology and Pneumology (U.K., M.G., X.W., F.E., M.G., C. Skurk, C.T., H.-P.S., W.P.), Institute for Biometry and Clinical Epidemiology, Campus Benjamin Franklin (A.S.), Institute for Medical Immunology, Campus Virchow Klinikum (M.L., C. Scheibenbogen), Berlin Center for Regenerative Therapies (BCRT) (C.T., M.L., C. Scheibenbogen, W.P.), Charité-Universitätsmedizin Berlin, Berlin, Germany; and Institute for Cardiac Diagnostics and Therapy (IKDT), Berlin, Germany (D.L., M.R., C. Siegismund)
| | - Martina Gast
- From the Department of Cardiology and Pneumology (U.K., M.G., X.W., F.E., M.G., C. Skurk, C.T., H.-P.S., W.P.), Institute for Biometry and Clinical Epidemiology, Campus Benjamin Franklin (A.S.), Institute for Medical Immunology, Campus Virchow Klinikum (M.L., C. Scheibenbogen), Berlin Center for Regenerative Therapies (BCRT) (C.T., M.L., C. Scheibenbogen, W.P.), Charité-Universitätsmedizin Berlin, Berlin, Germany; and Institute for Cardiac Diagnostics and Therapy (IKDT), Berlin, Germany (D.L., M.R., C. Siegismund)
| | - Andrea Stroux
- From the Department of Cardiology and Pneumology (U.K., M.G., X.W., F.E., M.G., C. Skurk, C.T., H.-P.S., W.P.), Institute for Biometry and Clinical Epidemiology, Campus Benjamin Franklin (A.S.), Institute for Medical Immunology, Campus Virchow Klinikum (M.L., C. Scheibenbogen), Berlin Center for Regenerative Therapies (BCRT) (C.T., M.L., C. Scheibenbogen, W.P.), Charité-Universitätsmedizin Berlin, Berlin, Germany; and Institute for Cardiac Diagnostics and Therapy (IKDT), Berlin, Germany (D.L., M.R., C. Siegismund)
| | - Maria Rohde
- From the Department of Cardiology and Pneumology (U.K., M.G., X.W., F.E., M.G., C. Skurk, C.T., H.-P.S., W.P.), Institute for Biometry and Clinical Epidemiology, Campus Benjamin Franklin (A.S.), Institute for Medical Immunology, Campus Virchow Klinikum (M.L., C. Scheibenbogen), Berlin Center for Regenerative Therapies (BCRT) (C.T., M.L., C. Scheibenbogen, W.P.), Charité-Universitätsmedizin Berlin, Berlin, Germany; and Institute for Cardiac Diagnostics and Therapy (IKDT), Berlin, Germany (D.L., M.R., C. Siegismund)
| | - Christine Siegismund
- From the Department of Cardiology and Pneumology (U.K., M.G., X.W., F.E., M.G., C. Skurk, C.T., H.-P.S., W.P.), Institute for Biometry and Clinical Epidemiology, Campus Benjamin Franklin (A.S.), Institute for Medical Immunology, Campus Virchow Klinikum (M.L., C. Scheibenbogen), Berlin Center for Regenerative Therapies (BCRT) (C.T., M.L., C. Scheibenbogen, W.P.), Charité-Universitätsmedizin Berlin, Berlin, Germany; and Institute for Cardiac Diagnostics and Therapy (IKDT), Berlin, Germany (D.L., M.R., C. Siegismund)
| | - Xiaomin Wang
- From the Department of Cardiology and Pneumology (U.K., M.G., X.W., F.E., M.G., C. Skurk, C.T., H.-P.S., W.P.), Institute for Biometry and Clinical Epidemiology, Campus Benjamin Franklin (A.S.), Institute for Medical Immunology, Campus Virchow Klinikum (M.L., C. Scheibenbogen), Berlin Center for Regenerative Therapies (BCRT) (C.T., M.L., C. Scheibenbogen, W.P.), Charité-Universitätsmedizin Berlin, Berlin, Germany; and Institute for Cardiac Diagnostics and Therapy (IKDT), Berlin, Germany (D.L., M.R., C. Siegismund)
| | - Felicitas Escher
- From the Department of Cardiology and Pneumology (U.K., M.G., X.W., F.E., M.G., C. Skurk, C.T., H.-P.S., W.P.), Institute for Biometry and Clinical Epidemiology, Campus Benjamin Franklin (A.S.), Institute for Medical Immunology, Campus Virchow Klinikum (M.L., C. Scheibenbogen), Berlin Center for Regenerative Therapies (BCRT) (C.T., M.L., C. Scheibenbogen, W.P.), Charité-Universitätsmedizin Berlin, Berlin, Germany; and Institute for Cardiac Diagnostics and Therapy (IKDT), Berlin, Germany (D.L., M.R., C. Siegismund)
| | - Michael Gross
- From the Department of Cardiology and Pneumology (U.K., M.G., X.W., F.E., M.G., C. Skurk, C.T., H.-P.S., W.P.), Institute for Biometry and Clinical Epidemiology, Campus Benjamin Franklin (A.S.), Institute for Medical Immunology, Campus Virchow Klinikum (M.L., C. Scheibenbogen), Berlin Center for Regenerative Therapies (BCRT) (C.T., M.L., C. Scheibenbogen, W.P.), Charité-Universitätsmedizin Berlin, Berlin, Germany; and Institute for Cardiac Diagnostics and Therapy (IKDT), Berlin, Germany (D.L., M.R., C. Siegismund)
| | - Carsten Skurk
- From the Department of Cardiology and Pneumology (U.K., M.G., X.W., F.E., M.G., C. Skurk, C.T., H.-P.S., W.P.), Institute for Biometry and Clinical Epidemiology, Campus Benjamin Franklin (A.S.), Institute for Medical Immunology, Campus Virchow Klinikum (M.L., C. Scheibenbogen), Berlin Center for Regenerative Therapies (BCRT) (C.T., M.L., C. Scheibenbogen, W.P.), Charité-Universitätsmedizin Berlin, Berlin, Germany; and Institute for Cardiac Diagnostics and Therapy (IKDT), Berlin, Germany (D.L., M.R., C. Siegismund)
| | - Carsten Tschoepe
- From the Department of Cardiology and Pneumology (U.K., M.G., X.W., F.E., M.G., C. Skurk, C.T., H.-P.S., W.P.), Institute for Biometry and Clinical Epidemiology, Campus Benjamin Franklin (A.S.), Institute for Medical Immunology, Campus Virchow Klinikum (M.L., C. Scheibenbogen), Berlin Center for Regenerative Therapies (BCRT) (C.T., M.L., C. Scheibenbogen, W.P.), Charité-Universitätsmedizin Berlin, Berlin, Germany; and Institute for Cardiac Diagnostics and Therapy (IKDT), Berlin, Germany (D.L., M.R., C. Siegismund)
| | - Madlen Loebel
- From the Department of Cardiology and Pneumology (U.K., M.G., X.W., F.E., M.G., C. Skurk, C.T., H.-P.S., W.P.), Institute for Biometry and Clinical Epidemiology, Campus Benjamin Franklin (A.S.), Institute for Medical Immunology, Campus Virchow Klinikum (M.L., C. Scheibenbogen), Berlin Center for Regenerative Therapies (BCRT) (C.T., M.L., C. Scheibenbogen, W.P.), Charité-Universitätsmedizin Berlin, Berlin, Germany; and Institute for Cardiac Diagnostics and Therapy (IKDT), Berlin, Germany (D.L., M.R., C. Siegismund)
| | - Carmen Scheibenbogen
- From the Department of Cardiology and Pneumology (U.K., M.G., X.W., F.E., M.G., C. Skurk, C.T., H.-P.S., W.P.), Institute for Biometry and Clinical Epidemiology, Campus Benjamin Franklin (A.S.), Institute for Medical Immunology, Campus Virchow Klinikum (M.L., C. Scheibenbogen), Berlin Center for Regenerative Therapies (BCRT) (C.T., M.L., C. Scheibenbogen, W.P.), Charité-Universitätsmedizin Berlin, Berlin, Germany; and Institute for Cardiac Diagnostics and Therapy (IKDT), Berlin, Germany (D.L., M.R., C. Siegismund)
| | - Heinz-Peter Schultheiss
- From the Department of Cardiology and Pneumology (U.K., M.G., X.W., F.E., M.G., C. Skurk, C.T., H.-P.S., W.P.), Institute for Biometry and Clinical Epidemiology, Campus Benjamin Franklin (A.S.), Institute for Medical Immunology, Campus Virchow Klinikum (M.L., C. Scheibenbogen), Berlin Center for Regenerative Therapies (BCRT) (C.T., M.L., C. Scheibenbogen, W.P.), Charité-Universitätsmedizin Berlin, Berlin, Germany; and Institute for Cardiac Diagnostics and Therapy (IKDT), Berlin, Germany (D.L., M.R., C. Siegismund)
| | - Wolfgang Poller
- From the Department of Cardiology and Pneumology (U.K., M.G., X.W., F.E., M.G., C. Skurk, C.T., H.-P.S., W.P.), Institute for Biometry and Clinical Epidemiology, Campus Benjamin Franklin (A.S.), Institute for Medical Immunology, Campus Virchow Klinikum (M.L., C. Scheibenbogen), Berlin Center for Regenerative Therapies (BCRT) (C.T., M.L., C. Scheibenbogen, W.P.), Charité-Universitätsmedizin Berlin, Berlin, Germany; and Institute for Cardiac Diagnostics and Therapy (IKDT), Berlin, Germany (D.L., M.R., C. Siegismund).
| |
Collapse
|
70
|
Abstract
Heart failure is a global problem with an estimated prevalence of 38 million patients worldwide, a number that is increasing with the ageing of the population. It is the most common diagnosis in patients aged 65 years or older admitted to hospital and in high-income nations. Despite some progress, the prognosis of heart failure is worse than that of most cancers. Because of the seriousness of the condition, a declaration of war on five fronts has been proposed for heart failure. Efforts are underway to treat heart failure by enhancing myofilament sensitivity to Ca(2+); transfer of the gene for SERCA2a, the protein that pumps calcium into the sarcoplasmic reticulum of the cardiomyocyte, seems promising in a phase 2 trial. Several other abnormal calcium-handling proteins in the failing heart are candidates for gene therapy; many short, non-coding RNAs--ie, microRNAs (miRNAs)--block gene expression and protein translation. These molecules are crucial to calcium cycling and ventricular hypertrophy. The actions of miRNAs can be blocked by a new class of drugs, antagomirs, some of which have been shown to improve cardiac function in animal models of heart failure; cell therapy, with autologous bone marrow derived mononuclear cells, or autogenous mesenchymal cells, which can be administered as cryopreserved off the shelf products, seem to be promising in both preclinical and early clinical heart failure trials; and long-term ventricular assistance devices are now used increasingly as a destination therapy in patients with advanced heart failure. In selected patients, left ventricular assistance can lead to myocardial recovery and explantation of the device. The approaches to the treatment of heart failure described, when used alone or in combination, could become important weapons in the war against heart failure.
Collapse
Affiliation(s)
- Eugene Braunwald
- TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.
| |
Collapse
|
71
|
Wong LL, Armugam A, Sepramaniam S, Karolina DS, Lim KY, Lim JY, Chong JPC, Ng JYX, Chen YT, Chan MMY, Chen Z, Yeo PSD, Ng TP, Ling LH, Sim D, Leong KTG, Ong HY, Jaufeerally F, Wong R, Chai P, Low AF, Lam CSP, Jeyaseelan K, Richards AM. Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail 2015; 17:393-404. [PMID: 25619197 DOI: 10.1002/ejhf.223] [Citation(s) in RCA: 145] [Impact Index Per Article: 16.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/31/2014] [Revised: 11/11/2014] [Accepted: 11/14/2014] [Indexed: 01/15/2023] Open
Abstract
AIM The potential diagnostic utility of circulating microRNAs in heart failure (HF) or in distinguishing HF with reduced vs. preserved left ventricular ejection fraction (HFREF and HFPEF, respectively) is unclear. We sought to identify microRNAs suitable for diagnosis of HF and for distinguishing both HFREF and HFPEF from non-HF controls and HFREF from HFPEF. METHODS AND RESULTS MicroRNA profiling performed on whole blood and corresponding plasma samples of 28 controls, 39 HFREF and 19 HFPEF identified 344 microRNAs to be dysregulated among the three groups. Further analysis using an independent cohort of 30 controls, 30 HFREF and 30 HFPEF, presented 12 microRNAs with diagnostic potential for one or both HF phenotypes. Of these, miR-1233, -183-3p, -190a, -193b-3p, -193b-5p, -211-5p, -494, and -671-5p distinguished HF from controls. Altered levels of miR-125a-5p, -183-3p, -193b-3p, -211-5p, -494, -638, and -671-5p were found in HFREF while levels of miR-1233, -183-3p, -190a, -193b-3p, -193b-5p, and -545-5p distinguished HFPEF from controls. Four microRNAs (miR-125a-5p, -190a, -550a-5p, and -638) distinguished HFREF from HFPEF. Selective microRNA panels showed stronger discriminative power than N-terminal pro-brain natriuretic peptide (NT-proBNP). In addition, individual or multiple microRNAs used in combination with NT-proBNP increased NT-proBNP's discriminative performance, achieving perfect intergroup distinction. Pathway analysis revealed that the altered microRNAs expression was associated with several mechanisms of potential significance in HF. CONCLUSIONS We report specific microRNAs as potential biomarkers in distinguishing HF from non-HF controls and in differentiating between HFREF and HFPEF.
Collapse
Affiliation(s)
- Lee Lee Wong
- Cardiovascular Research Institute, Singapore; Department of Medicine, Singapore
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
72
|
Keller A, Leidinger P, Vogel B, Backes C, ElSharawy A, Galata V, Mueller SC, Marquart S, Schrauder MG, Strick R, Bauer A, Wischhusen J, Beier M, Kohlhaas J, Katus HA, Hoheisel J, Franke A, Meder B, Meese E. miRNAs can be generally associated with human pathologies as exemplified for miR-144. BMC Med 2014; 12:224. [PMID: 25465851 PMCID: PMC4268797 DOI: 10.1186/s12916-014-0224-0] [Citation(s) in RCA: 67] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/09/2014] [Accepted: 11/04/2014] [Indexed: 01/28/2023] Open
Abstract
BACKGROUND miRNA profiles are promising biomarker candidates for a manifold of human pathologies, opening new avenues for diagnosis and prognosis. Beyond studies that describe miRNAs frequently as markers for specific traits, we asked whether a general pattern for miRNAs across many diseases exists. METHODS We evaluated genome-wide circulating profiles of 1,049 patients suffering from 19 different cancer and non-cancer diseases as well as unaffected controls. The results were validated on 319 individuals using qRT-PCR. RESULTS We discovered 34 miRNAs with strong disease association. Among those, we found substantially decreased levels of hsa-miR-144* and hsa-miR-20b with AUC of 0.751 (95% CI: 0.703-0.799), respectively. We also discovered a set of miRNAs, including hsa-miR-155*, as rather stable markers, offering reasonable control miRNAs for future studies. The strong downregulation of hsa-miR-144* and the less variable pattern of hsa-miR-155* has been validated in a cohort of 319 samples in three different centers. Here, breast cancer as an additional disease phenotype not included in the screening phase has been included as the 20th trait. CONCLUSIONS Our study on 1,368 patients including 1,049 genome-wide miRNA profiles and 319 qRT-PCR validations further underscores the high potential of specific blood-borne miRNA patterns as molecular biomarkers. Importantly, we highlight 34 miRNAs that are generally dysregulated in human pathologies. Although these markers are not specific to certain diseases they may add to the diagnosis in combination with other markers, building a specific signature. Besides these dysregulated miRNAs, we propose a set of constant miRNAs that may be used as control markers.
Collapse
Affiliation(s)
- Andreas Keller
- Chair for Clinical Bioinformatics, Saarland University, Saarbrücken, Germany.
| | - Petra Leidinger
- Institute of Human Genetics, Saarland University, Homburg, Germany.
| | - Britta Vogel
- Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany.
| | - Christina Backes
- Chair for Clinical Bioinformatics, Saarland University, Saarbrücken, Germany.
| | - Abdou ElSharawy
- Institute of Clinical Molecular Biology, Christian-Albrechts-University Kiel, Kiel, Germany.
| | - Valentina Galata
- Chair for Clinical Bioinformatics, Saarland University, Saarbrücken, Germany.
| | - Sabine C Mueller
- Chair for Clinical Bioinformatics, Saarland University, Saarbrücken, Germany.
| | - Sabine Marquart
- Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany.
| | - Michael G Schrauder
- Department of Gynecology and Obstetrics, University Breast Center Franconia, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
| | - Reiner Strick
- Department of Gynecology and Obstetrics, University Breast Center Franconia, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
| | - Andrea Bauer
- German Cancer Research Center, Heidelberg, Germany.
| | | | - Markus Beier
- Comprehensive Biomarker Center, Heidelberg, Germany.
| | | | - Hugo A Katus
- Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany.
- German Center for Cardiovascular Research - DZHK, Germany, Heidelberg.
| | | | - Andre Franke
- Institute of Clinical Molecular Biology, Christian-Albrechts-University Kiel, Kiel, Germany.
| | - Benjamin Meder
- Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany.
- German Center for Cardiovascular Research - DZHK, Germany, Heidelberg.
| | - Eckart Meese
- Institute of Human Genetics, Saarland University, Homburg, Germany.
| |
Collapse
|
73
|
Haas J, Frese KS, Peil B, Kloos W, Keller A, Nietsch R, Feng Z, Müller S, Kayvanpour E, Vogel B, Sedaghat-Hamedani F, Lim WK, Zhao X, Fradkin D, Köhler D, Fischer S, Franke J, Marquart S, Barb I, Li DT, Amr A, Ehlermann P, Mereles D, Weis T, Hassel S, Kremer A, King V, Wirsz E, Isnard R, Komajda M, Serio A, Grasso M, Syrris P, Wicks E, Plagnol V, Lopes L, Gadgaard T, Eiskjær H, Jørgensen M, Garcia-Giustiniani D, Ortiz-Genga M, Crespo-Leiro MG, Deprez RHLD, Christiaans I, van Rijsingen IA, Wilde AA, Waldenstrom A, Bolognesi M, Bellazzi R, Mörner S, Bermejo JL, Monserrat L, Villard E, Mogensen J, Pinto YM, Charron P, Elliott P, Arbustini E, Katus HA, Meder B. Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J 2014; 36:1123-35a. [DOI: 10.1093/eurheartj/ehu301] [Citation(s) in RCA: 367] [Impact Index Per Article: 36.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/22/2014] [Indexed: 12/18/2022] Open
|
74
|
Abstract
The last years have witnessed tremendous technical advances in the field of transcriptomics that enable the simultaneous assessment of nearly all transcripts expressed in a tissue at a given time. These advances harbor the potential to gain a better understanding of the complex biological systems and for the identification and development of novel biomarkers. This article will review the current knowledge of transcriptomics biomarkers in the cardiovascular field and will provide an overview about the promises and challenges of the transcriptomics approach for biomarker identification.
Collapse
Affiliation(s)
- Marten Antoon Siemelink
- />Laboratory of Experimental Cardiology, University Medical Center Utrecht, Heidelberglaanes 100 Room G02.523, PO Box 85500, 3508 GA Utrecht, The Netherlands
| | - Tanja Zeller
- />Clinic for General and Interventional Cardiology, University Heart Center Hamburg, Martinistr. 52, 20246 Hamburg, Germany
- />German Center for Cardiovascular Research (DZHK), Hamburg/Lübeck/Kiel Partner Site, Hamburg, Germany
| |
Collapse
|
75
|
Meder B, Backes C, Haas J, Leidinger P, Stähler C, Großmann T, Vogel B, Frese K, Giannitsis E, Katus HA, Meese E, Keller A. Influence of the confounding factors age and sex on microRNA profiles from peripheral blood. Clin Chem 2014; 60:1200-8. [PMID: 24987111 DOI: 10.1373/clinchem.2014.224238] [Citation(s) in RCA: 83] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
BACKGROUND MicroRNAs (miRNAs) measured from blood samples are promising minimally invasive biomarker candidates that have been extensively studied in several case-control studies. However, the influence of age and sex as confounding variables remains largely unknown. METHODS We systematically explored the impact of age and sex on miRNAs in a cohort of 109 physiologically unaffected individuals whose blood was characterized by microarray technology (stage 1). We also investigated an independent cohort from a different institution consisting of 58 physiologically unaffected individuals having a similar mean age but with a smaller age distribution. These samples were measured by use of high-throughput sequencing (stage 2). RESULTS We detected 318 miRNAs that were significantly correlated with age in stage 1 and, after adjustment for multiple testing of 35 miRNAs, remained statistically significant. Regarding sex, 144 miRNAs showed significant dysregulation. Here, no miRNA remained significant after adjustment for multiple testing. In the high-throughput datasets of stage 2, we generally observed a smaller number of significant associations, mainly as an effect of the smaller cohort size and age distribution. Nevertheless, we found 7 miRNAs that were correlated with age, of which 5 were concordant with stage 1. CONCLUSIONS The age distribution of individuals recruited for case-control studies needs to be carefully considered, whereas sex may be less confounding. To support the translation of miRNAs into clinical application, we offer a web-based application (http://www.ccb.uni-saarland.de/mirnacon) to test individual miRNAs or miRNA signatures for their likelihood of being influenced.
Collapse
Affiliation(s)
- Benjamin Meder
- Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany; DZHK (German Centre for Cardiovascular Research), Heidelberg, Germany; Klaus Tschira Institute for Integrative Computational Cardiology, Heidelberg, Germany
| | - Christina Backes
- Department of Human Genetics, Saarland University, Homburg, Germany
| | - Jan Haas
- Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany; DZHK (German Centre for Cardiovascular Research), Heidelberg, Germany
| | - Petra Leidinger
- Department of Human Genetics, Saarland University, Homburg, Germany
| | | | - Thomas Großmann
- Clinical Bioinformatics, Saarland University, Saarbrucken, Germany
| | - Britta Vogel
- Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany
| | - Karen Frese
- Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany
| | - Evangelos Giannitsis
- Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany
| | - Hugo A Katus
- Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany; DZHK (German Centre for Cardiovascular Research), Heidelberg, Germany; Klaus Tschira Institute for Integrative Computational Cardiology, Heidelberg, Germany
| | - Eckart Meese
- Department of Human Genetics, Saarland University, Homburg, Germany
| | - Andreas Keller
- Clinical Bioinformatics, Saarland University, Saarbrucken, Germany.
| |
Collapse
|
76
|
Leidinger P, Backes C, Meder B, Meese E, Keller A. The human miRNA repertoire of different blood compounds. BMC Genomics 2014; 15:474. [PMID: 24928098 PMCID: PMC4076980 DOI: 10.1186/1471-2164-15-474] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2014] [Accepted: 06/06/2014] [Indexed: 12/20/2022] Open
Abstract
Background MiRNAs from body fluids gain more and more attraction as biomarker candidates. Besides serum, patterns from whole blood are increasingly considered as markers for human pathologies. Usually, the contribution of different cell types to the respective signature remains however unknown. In this study we provide insights into the human miRNome of different compounds of the blood including CD3, CD14, CD15, CD19, CD56 positive cells as well as exosomes. Methods We measured the miRNA repertoire for each cell type and whole blood for two individuals at three time points over the course of one year in order to provide evidence that the cell type miRNomes can be reproducibly detected. Results For measurements repeated after 24 hours we found on average correlation of 0.97, even after one year profiles still correlated with 0.96, demonstrating the enormous stability of the cell type specific miRNomes. Highest correlation was found for CD15 positive cells, exceeding Pearson correlation of 0.99. For exosomes a significantly higher variability of miRNA expression was detected. In order to estimate the complexity and variability of the cell type specific miRNomes, we generated profiles for all considered cell types in a total of seven unaffected individuals. While CD15 positive cells showed the most complex miRNome consisting of 328 miRNAs, we detected significantly less miRNAs (186, p = 1.5*10-5) in CD19 positive cells. Moreover, our analysis showed functional enrichment in many relevant categories such as onco-miRNAs and tumor miRNA suppressors. Interestingly, exosomes were enriched just for onco-miRNAs but not for miRNA tumor suppressors. Conclusion In sum, our results provide evidence that blood cell type specific miRNomes are very consistent between individuals and over time.
Collapse
Affiliation(s)
| | | | | | | | - Andreas Keller
- Chair for Clinical Bioinformatics, Saarland University, Saarbrücken, Germany.
| |
Collapse
|
77
|
Ferreira LRP, Frade AF, Santos RHB, Teixeira PC, Baron MA, Navarro IC, Benvenuti LA, Fiorelli AI, Bocchi EA, Stolf NA, Chevillard C, Kalil J, Cunha-Neto E. MicroRNAs miR-1, miR-133a, miR-133b, miR-208a and miR-208b are dysregulated in Chronic Chagas disease Cardiomyopathy. Int J Cardiol 2014; 175:409-17. [PMID: 24910366 DOI: 10.1016/j.ijcard.2014.05.019] [Citation(s) in RCA: 73] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/02/2013] [Revised: 04/25/2014] [Accepted: 05/11/2014] [Indexed: 12/25/2022]
Abstract
BACKGROUND/METHODS Chagas disease is caused by an intracellular parasite, Trypanosoma cruzi, and it is a leading cause of heart failure in Latin America. The main clinical consequence of the infection is the development of a Chronic Chagas disease Cardiomyopathy (CCC), which is characterized by myocarditis, hypertrophy and fibrosis and affects about 30% of infected patients. CCC has a worse prognosis than other cardiomyopathies, like idiopathic dilated cardiomyopathy (DCM). It is well established that myocardial gene expression patterns are altered in CCC, but the molecular mechanisms underlying these differences are not clear. MicroRNAs are recently discovered regulators of gene expression, and are recognized as important factors in heart development and cardiovascular disorders (CD). We analyzed the expression of nine different miRNAs in myocardial tissue samples of CCC patients in comparison to DCM patients and samples from heart transplant donors. Using the results of a cDNA microarray database on CCC and DCM myocardium, signaling networks were built and nodal molecules were identified. RESULTS We observed that five miRNAs were significantly altered in CCC and three in DCM; importantly, three miRNAs were significantly reduced in CCC as compared to DCM. We observed that multiple gene targets of the differentially expressed miRNAs showed a concordant inverse expression in CCC. Significantly, most gene targets and involved networks belong to crucial disease-related signaling pathways. CONCLUSION These results suggest that miRNAs may play a major role in the regulation of gene expression in CCC pathogenesis, with potential implication as diagnostic and prognostic tools.
Collapse
Affiliation(s)
- Ludmila Rodrigues Pinto Ferreira
- Laboratory of Immunology, Heart Institute (InCor), University of São Paulo, School of Medicine, São Paulo, Brazil; Division of Clinical Immunology and Allergy, University of São Paulo, School of Medicine, São Paulo, Brazil; Institute for Investigation in Immunology (iii), INCT, 05403-001, São Paulo, Brazil
| | - Amanda Farage Frade
- Laboratory of Immunology, Heart Institute (InCor), University of São Paulo, School of Medicine, São Paulo, Brazil; Division of Clinical Immunology and Allergy, University of São Paulo, School of Medicine, São Paulo, Brazil; Institute for Investigation in Immunology (iii), INCT, 05403-001, São Paulo, Brazil
| | | | - Priscila Camillo Teixeira
- Laboratory of Immunology, Heart Institute (InCor), University of São Paulo, School of Medicine, São Paulo, Brazil; Division of Clinical Immunology and Allergy, University of São Paulo, School of Medicine, São Paulo, Brazil; Institute for Investigation in Immunology (iii), INCT, 05403-001, São Paulo, Brazil
| | - Monique Andrade Baron
- Laboratory of Immunology, Heart Institute (InCor), University of São Paulo, School of Medicine, São Paulo, Brazil; Division of Clinical Immunology and Allergy, University of São Paulo, School of Medicine, São Paulo, Brazil; Institute for Investigation in Immunology (iii), INCT, 05403-001, São Paulo, Brazil
| | - Isabela Cunha Navarro
- Laboratory of Immunology, Heart Institute (InCor), University of São Paulo, School of Medicine, São Paulo, Brazil; Division of Clinical Immunology and Allergy, University of São Paulo, School of Medicine, São Paulo, Brazil; Institute for Investigation in Immunology (iii), INCT, 05403-001, São Paulo, Brazil
| | - Luiz Alberto Benvenuti
- Division of Pathology, Heart Institute (InCor), University of São Paulo, School of Medicine, São Paulo, Brazil
| | - Alfredo Inácio Fiorelli
- Division of Surgery, Heart Institute (InCor), University of São Paulo, School of Medicine, São Paulo, Brazil
| | - Edimar Alcides Bocchi
- Division of Surgery, Heart Institute (InCor), University of São Paulo, School of Medicine, São Paulo, Brazil
| | - Noedir Antonio Stolf
- Division of Surgery, Heart Institute (InCor), University of São Paulo, School of Medicine, São Paulo, Brazil
| | | | - Jorge Kalil
- Division of Clinical Immunology and Allergy, University of São Paulo, School of Medicine, São Paulo, Brazil; Institute for Investigation in Immunology (iii), INCT, 05403-001, São Paulo, Brazil
| | - Edecio Cunha-Neto
- Laboratory of Immunology, Heart Institute (InCor), University of São Paulo, School of Medicine, São Paulo, Brazil; Division of Clinical Immunology and Allergy, University of São Paulo, School of Medicine, São Paulo, Brazil; Institute for Investigation in Immunology (iii), INCT, 05403-001, São Paulo, Brazil..
| |
Collapse
|
78
|
Kontaraki JE, Marketou ME, Zacharis EA, Parthenakis FI, Vardas PE. MicroRNA-9 and microRNA-126 expression levels in patients with essential hypertension: potential markers of target-organ damage. ACTA ACUST UNITED AC 2014; 8:368-75. [PMID: 24794206 DOI: 10.1016/j.jash.2014.03.324] [Citation(s) in RCA: 85] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2014] [Revised: 03/21/2014] [Accepted: 03/21/2014] [Indexed: 12/21/2022]
Abstract
MicroRNAs (miRs), as essential gene expression regulators, modulate cardiovascular development and disease and thus they are emerging as potential biomarkers and therapeutic targets in cardiovascular disease, including hypertension. We assessed the expression levels of the microRNAs miR-9 and miR-126 in 60 patients with untreated essential hypertension and 29 healthy individuals. All patients underwent two-dimensional echocardiography and 24-hour ambulatory blood pressure monitoring. MicroRNA expression levels in peripheral blood mononuclear cells were quantified by real-time reverse transcription polymerase chain reaction. Hypertensive patients showed significantly lower miR-9 (9.69 ± 1.56 vs 41.08 ± 6.06; P < .001) and miR-126 (3.88 ± 0.47 vs 8.96 ± 1.69; P < .001) expression levels compared with healthy controls. In hypertensive patients, miR-9 expression levels showed a significant positive correlation (r = 0.437; P < .001) with left ventricular mass index. Furthermore, both miR-9 (r = 0.312; P = .015) and miR-126 (r = 0.441; P < .001) expression levels in hypertensive patients showed significant positive correlations with the 24-hour mean pulse pressure. Our data reveal that miR-9 and miR-126 are closely related to essential hypertension in humans, as they show a distinct expression profile in hypertensive patients relative to healthy individuals, and they are associated with clinical prognostic indices of hypertensive target-organ damage in hypertensive patients. Thus, they may possibly represent potential biomarkers and candidate therapeutic targets in essential hypertension.
Collapse
Affiliation(s)
- Joanna E Kontaraki
- Molecular Cardiology Laboratory, School of Medicine, University of Crete, Greece.
| | - Maria E Marketou
- Department of Cardiology, Heraklion University Hospital, Crete, Greece
| | | | | | - Panos E Vardas
- Department of Cardiology, Heraklion University Hospital, Crete, Greece
| |
Collapse
|
79
|
Condorelli G, Latronico MVG, Cavarretta E. microRNAs in cardiovascular diseases: current knowledge and the road ahead. J Am Coll Cardiol 2014; 63:2177-87. [PMID: 24583309 DOI: 10.1016/j.jacc.2014.01.050] [Citation(s) in RCA: 285] [Impact Index Per Article: 28.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/10/2013] [Revised: 01/17/2014] [Accepted: 01/28/2014] [Indexed: 12/15/2022]
Abstract
Over the last few years, the field of microribonucleic acid (miRNA) in cardiovascular biology and disease has expanded at an incredible pace. miRNAs are themselves part of a larger family, that of non-coding RNAs, the importance of which for biological processes is starting to emerge. miRNAs are ~22-nucleotide-long RNA sequences that can legate messenger (m)RNAs at partially complementary binding sites, and hence regulate the rate of protein synthesis by altering the stability of the targeted mRNAs. In the cardiovascular system, miRNAs have been shown to be critical regulators of development and physiology. They control basic functions in virtually all cell types relevant to the cardiovascular system (such as endothelial cells, cardiac muscle, smooth muscle, inflammatory cells, and fibroblasts) and, thus, are directly involved in the pathophysiology of many cardiovascular diseases. As a result of their role in disease, they are being studied for exploitation in diagnostics, prognostics, and therapeutics. However, there are still significant obstacles that need to be overcome before they enter the clinical arena. We present here a review of the literature and outline the directions toward their use in the clinic.
Collapse
Affiliation(s)
- Gianluigi Condorelli
- Cardiovascular Research Center, Humanitas Research Hospital, Rozzano, Italy; Department of Medical Biotechnologies and Translational Medicine, University of Milan, Rozzano, Italy; Institute of Genetics and Biomedical Research, National Research Council of Italy, Rome, Italy.
| | | | - Elena Cavarretta
- Department of Medical-Surgical Sciences and Biotechnologies, University of Rome "La Sapienza", Latina, Italy
| |
Collapse
|
80
|
Sawada S, Akimoto T, Takahashi M, Sakurai R, Shinkai S, Ushida T, Fujiwara Y, Suzuki K. Effect of Aging and Sex on Circulating MicroRNAs in Humans. ACTA ACUST UNITED AC 2014. [DOI: 10.4236/aar.2014.32023] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
81
|
Liu LCY, Damman K, Lipsic E, Maass AH, Rienstra M, Westenbrink BD. Heart failure highlights in 2012-2013. Eur J Heart Fail 2013; 16:122-32. [PMID: 24464645 DOI: 10.1002/ejhf.43] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/21/2013] [Revised: 11/04/2013] [Accepted: 11/08/2013] [Indexed: 01/10/2023] Open
Abstract
Heart failure has become the cardiovascular epidemic of the century. The European Journal of Heart Failure is dedicated to the advancement of knowledge in the field of heart failure management. In 2012 and 2013, several pioneering scientific discoveries and paradigm-shifting clinical trials have been published. In the current paper, we will discuss the most significant novel insights into the pathophysiology, diagnosis, and treatment of heart failure that were published during this period. All relevant research areas are discussed, including pathophysiology, co-morbidities, arrhythmias, biomarkers, clinical trials, and device therapy, including left ventricular assist devices.
Collapse
Affiliation(s)
- Licette C Y Liu
- The Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | | | | | | | | | | |
Collapse
|
82
|
Affiliation(s)
- Manuel Mayr
- King's British Heart Foundation Centre, King's College London, UK; and
| | | | | |
Collapse
|